Trials / Completed
CompletedNCT03495817
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
Detailed description
This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-50002 | ATI-50002 Topical Solution |
Timeline
- Start date
- 2018-03-22
- Primary completion
- 2019-10-15
- Completion
- 2019-10-30
- First posted
- 2018-04-12
- Last updated
- 2020-12-09
- Results posted
- 2020-12-09
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03495817. Inclusion in this directory is not an endorsement.